ALIPAY
12.7.2021 04:10:06 CEST | Business Wire | Press release
Portuguese football star Cristiano Ronaldo today became the winner of the Gold Trophy of the Alipay Top Scorer Awards at UEFA EURO 2020. Regarded as one of the greatest footballers of all time, Ronaldo netted five goals and made one assist at the competition. Patrik Schick from the Czech Republic was awarded the Silver Trophy, scoring five goals, while France’s Karim Benzema was the recipient of the Bronze Trophy, netting four goals.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210711005035/en/
The Alipay Top Scorer trophies are the first major international football Top-Scorer trophies to embed blockchain in their design, incorporating a hash code at the base through which scoring records of the tournament’s top three scorers can be uploaded and permanently stored on a blockchain powered by AntChain. Using the hash code provided, Alipay will upload the trophy data to the blockchain, ensuring a permanent, immutable record of the top scorers’ achievements.
“Our warmest congratulations to Cristiano Ronaldo for his phenomenal performances at UEFA EURO 2020, and for winning the Alipay Top Scorer Gold Award,” said Eric Jing, Chairman and CEO of Ant Group, who presented the top scorer trophies via video from Hangzhou immediately after the final game of UEFA EURO 2020. “Just as we have used blockchain technology to permanently preserve the wonderful scoring moments of the top scorers like him, we will also keep working with UEFA, to explore innovative digital solutions that improve fans’ experiences while enjoying football.”
UEFA and AntChain, one of the technology brands of Ant Group, on June 10 announced a five-year global partnership to jointly explore using blockchain technology to accelerate the digital transformation of the football industry and improve the experiences of fans across the globe. Under the agreement, AntChain became the official global blockchain partner of UEFA EURO 2020.
To honor the performances of the top scoring players, an AntChain-developed digital record of highlights from the UEFA EURO 2020 top scorers will be preserved at UEFA’s headquarters, making it the first digital collectible in the history of the EURO Top Scorer.
“The top scoring moments digital collectible will serve as a lasting memento, encouraging football fans around the world to spread the team spirit and happiness that are part and parcel of this beloved sport,” said Mr. Jing.
The UEFA EURO 2020 Top Scorer trophies are designed by Alipay, the world’s leading digital payment and lifestyle platform operated by Ant Group, which has been UEFA’s global partner since November 2018.
On June 12, UEFA launched a new mini program with Alipay to improve engagement with mobile-savvy Chinese football fans. Dubbed the UEFA EURO 2020 Official Digital Hub, the mini program offers football fans across China an inside look at the tournament through regular news updates, interviews with key players, and much more. The UEFA mini program has rapidly become the most popular sports-focused mini program on Alipay, attracting over 12 million users as of July 11.
During the tournament, Alipay launched a campaign via the UEFA EURO 2020 Dream Tour mini program that enables authenticated users to earn points by engaging in various fan activities. Powered by AntChain's technologies, the top 1,600 users will receive gold, silver, and bronze digital trophies as a form of digital souvenir with certificates on a blockchain.
Alipay also launched "Top Scorers on Campus,” a new advocacy program dedicated to supporting the development of campus football in China. To inspire more teenagers to pursue their football dreams, the program will award trophies with the same design as the Alipay Top Scorer Gold Trophy of the UEFA EURO 2020 to the best young players in campus football tournaments across China. Similar to the UEFA EURO 2020 Top Scorer Trophy, these students’ scoring records and achievements will also be stored on a blockchain provided by AntChain.
About AntChain
AntChain is one of Ant Group’s technology brands. According to IPR Daily and patent database IncoPat, Ant Group held the highest number of published blockchain-related patent applications between 2017 and the six months ended June 30, 2020. Since the launch of Ant Group’s blockchain business in 2016, the company has pioneered the use of AntChain in over 50 blockchain commercial applications and use cases, including supply chain finance, cross-border remittance, charitable donations, and product provenance.
About Alipay
Alipay is the leading digital payment platform in China, serving hundreds of millions of users, and connecting them with merchants and partner financial institutions that offer inclusive financial services and digital daily life services such as food delivery, transport, entertainment, and healthcare.
Ant Group has further introduced Alipay+, the global cross-border mobile payments and marketing solution which enables merchants, especially small and medium-sized businesses, to better serve consumers from all over the world by collaborating with global partners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210711005035/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom